June 2 (Bloomberg) -- NPS Pharmaceuticals Inc. said it hasn’t received any overtures from Shire Plc or any of the Dublin-based drug company’s representatives about a possible acquisition.
Bloomberg News reported May 30 that NPS hadn’t been contacted by Shire, according to a personal familiar with the matter. The Financial Times’ Alphaville website reported on May 30 that Shire has held internal discussions about a possible cash offer for NPS, the Bedminster, New Jersey-based company that makes medicines for rare diseases. Shire has been adding drugs for rare diseases to lessen its dependence on its best-selling pill for attention deficit hyperactivity disorder.
NPS hasn’t been approached about a potential takeover, the company said today in a filing with the Securities and Exchange Commission.
NPS said it released the statement because of “erroneous press reports” that Shire had communicated with the company. NPS said it will return to its policy of not commenting on rumors or speculation, and makes no promises to update the information it provided today to regulators.
To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at email@example.com
To contact the editors responsible for this story: Reg Gale at firstname.lastname@example.org Andrew Pollack, John Lear